Post Acute Analytics
PrivateLast Round
VC Round
Jul 18, 2025
Est. Valuation
$178M
Total Funding Raised
$9.9M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Post Acute Analytics operates in Healthcare & Life Sciences and is based in Irving, Texas. Its latest recorded funding round was a VC Round in July 2025.
Post Acute Analytics is a healthcare technology company that provides a clinical intelligence platform and real-time tracking solutions to improve patient outcomes and reduce the total cost of care across the post-acute continuum.
Sector
Healthcare & Life Sciences
Verticals
Healthcare Analytics, EHR & EMR, Business Intelligence, Vertical SaaS
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Post Acute Analytics Comparables
Compare Post Acute Analytics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aidin | 89% | |
| Real Time Medical Systems | 85% | |
| WellSky | 80% |
For institutional investors. Book with your work email.
Post Acute Analytics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jul 18, 2025 | ||||
| Series C | Jun 16, 2022 | ||||
| Series C | Mar 24, 2022 | ||||
| Series B | Jan 25, 2021 | ||||
| Debt | Dec 20, 2019 | ||||
Seed | Sep 18, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Post Acute Analytics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dorilton Ventures | Series C |
| Dorilton Capital | VC Round, Series B |
| Generator Ventures | Series C, Seed, VC Round, Series B |
| Dorilton Ventures | Series C |
| Warburg Pincus | VC Round, Series C |
| Concord Health Partners | Series C, Series B |
| Rubicon Founders | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors grew 91% MoM, reaching 3.4K.
- Aug 20, 2026
Monthly visitors grew 35% MoM, from 1.3K to 1.8K.
For institutional investors. Book with your work email.
Post Acute Analytics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Post Acute Analytics's valuation, stock price, and market status.
Is Post Acute Analytics a public or private company?
Post Acute Analytics is a private company.
What is the current stock price of Post Acute Analytics?
Post Acute Analytics is a private company, so its shares have no public market price. Caplight tracks Post Acute Analytics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Post Acute Analytics worth (valuation)?
Post Acute Analytics's valuation is estimated at $178.0M based on funding round data.
Can I buy Post Acute Analytics stock?
Post Acute Analytics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Post Acute Analytics's last funding round?
Post Acute Analytics's most recent funding round was VC Round on July 18, 2025.
Who are the main investors in Post Acute Analytics?
Key investors in Post Acute Analytics include Dorilton Ventures, Dorilton Capital, Dorilton Ventures, Warburg Pincus, Concord Health Partners.
Will Post Acute Analytics IPO soon?
No public IPO plans have been announced for Post Acute Analytics.
How can I track Post Acute Analytics secondary market activity?
Caplight tracks bids, offers, and trades in Post Acute Analytics's shares on secondary markets.